Selpercatinib shows survival benefits in medullary thyroid carcinoma
A re-evaluation of selpercatinib as a first-line treatment for advanced RET-mutated medullary thyroid carcinoma has shown a significant additional benefit compared to the comparator therapies vandetanib and cabozantinib. The Institute for Quality and Efficiency in Health Care (IQWiG) carried out the assessment on the basis of new data from the phase 3 LIBRETTO-531 study, after an earlier benefit assessment in 2023 was limited due to a lack of study results.
Selpercatinib, a selective RET kinase inhibitor, blocks a mutant enzyme in cancer cells that promotes their growth, thus inhibiting cell division. The LIBRETTO-531 study shows clear advantages in overall survival: Only five percent of patients died in the selpercatinib arm, compared to 16 percent in the comparator arm. Benefits were also found in other endpoints such as fatigue, pain and health-related quality of life.
The results of the dossier evaluation are incorporated into the early benefit assessment in accordance with the Drug Market Reorganization Act (AMNOG). The Federal Joint Committee (G-BA) is now conducting a comment procedure to finally decide on the extent of the additional benefit.
Original Paper:
Editor: X-Press Journalistenbüro GbR
Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.
Most read
Severe botulism outbreak in Italy: Four deaths and numerous illnesses In Italy, a severe outbreak of botulism in the regions of Calabria and Sardinia has caused great con...- Hannover Medical School mourns the loss of Prof. Dr. Michael P. Manns Die Medizinische Hochschule Hannover (MHH) trauert um ihren ehemaligen Präsidenten und weltweit reno...
- New hope for people with rectal cancer A research team from Mannheim and Heidelberg has developed a promising approach to improve the treat...
